Ticker Details
Kura Oncology, Inc. Kura Oncology Inc is a clinical stage biopharmaceutical company, engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers.
IPO Date:	September 16, 2015
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$1.07B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.41 | 3.06%
Avg Daily Range (30 D):	$0.34 | 3.35%
Avg Daily Range (90 D):	$0.26 | 2.78%

Institutional Daily Volume
Avg Daily Volume:	.57M
Avg Daily Volume (30 D):	1.56M
Avg Daily Volume (90 D):	1.41M

Trade Size
Avg Trade Size (Sh.):	91
Avg Trade Size (Sh.) (30 D):	79
Avg Trade Size (Sh.) (90 D):	83

Institutional Trades
Total Institutional Trades:	3,169
Avg Institutional Trade:	$1.84M
Avg Institutional Trade (30 D):	$2.57M
Avg Institutional Trade (90 D):	$1.91M
Avg Institutional Trade Volume:	.13M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.99M
Avg Closing Trade (30 D):	$3.16M
Avg Closing Trade (90 D):	$2.27M
Avg Closing Volume:	140.75K

News

Apr 24, 2026 @ 12:00 PM Kyowa Kirin and Kura Oncology Initiate Japanese Ph... Source: Na

Apr 17, 2026 @ 10:00 AM Kura Oncology Reports Darlifarnib Plus Cabozantini... Source: Na

Apr 3, 2026 @ 11:30 AM Kura Oncology Reports Inducement Grants Under Nasd... Source: Na

Dec 4, 2025 @ 5:20 PM Blood Cancer Therapeutics Reach Critical Commercia... Source: Prnewswire

Nov 25, 2025 @ 10:16 PM KOMZIFTIâ„¢ (ziftomenib) Added to National Com... Source: Kura Oncology And Kyowa Kirin

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$-3.35	$-.83	$-.92
Diluted EPS	$-3.35	$-.83	$-.92
Revenue	$71.64M	$18.27M	$17.34M
Gross Profit		$18M
Net Income / Loss	$-294.57M	$-73.33M	$-81M
Operating Income / Loss	$-317.75M	$-78.82M	$-86.27M
Cost of Revenue		$.26M
Net Cash Flow	$-12.19M	$-110.02M	$53.81M
PE Ratio